How Analysts Feel About Axsome Therapeutics Incorporated (NASDAQ:AXSM) After Decrease in Sellers?

December 7, 2017 - By Maria Brooks

 How Analysts Feel About Axsome Therapeutics Incorporated (NASDAQ:AXSM) After Decrease in Sellers?

The stock of Axsome Therapeutics Incorporated (NASDAQ:AXSM) registered a decrease of 12.32% in short interest. AXSM’s total short interest was 474,100 shares in December as published by FINRA. Its down 12.32% from 540,700 shares, reported previously. With 104,200 shares average volume, it will take short sellers 5 days to cover their AXSM’s short positions. The short interest to Axsome Therapeutics Incorporated’s float is 3.81%.

The stock increased 1.09% or $0.05 during the last trading session, reaching $4.65. About 91,365 shares traded. Axsome Therapeutics, Inc. (NASDAQ:AXSM) has declined 59.08% since December 7, 2016 and is downtrending. It has underperformed by 75.78% the S&P500.

Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the management of central nervous system disorders. The company has market cap of $118.34 million. The companyÂ’s product candidates include AXS-05 that is in Phase III trial for the treatment of treatment resistant depression and AlzheimerÂ’s disease agitation; and AXS-02, which is in Phase III trial to treat complex regional pain syndrome, knee osteoarthritis related to bone marrow lesions, and chronic low back pain related to Modic changes. It currently has negative earnings. It is also developing AXS-06, a preclinical product candidate for CNS disorders, including chronic pain.

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Ratings Coverage

Among 3 analysts covering Axsome Therapeutics (NASDAQ:AXSM), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Axsome Therapeutics had 3 analyst reports since December 14, 2015 according to SRatingsIntel. The rating was initiated by Ladenburg Thalmann with “Buy” on Monday, December 14. The rating was initiated by Cantor Fitzgerald on Tuesday, December 15 with “Buy”. Brean Capital initiated Axsome Therapeutics, Inc. (NASDAQ:AXSM) on Monday, October 3 with “Buy” rating.

More notable recent Axsome Therapeutics, Inc. (NASDAQ:AXSM) news were published by: which released: “Axsome Therapeutics Reports First Quarter 2017 Financial Results” on May 09, 2017, also with their article: “Axsome Therapeutics Announces $9.5 Million Registered Direct Offering Priced …” published on December 01, 2017, published: “Axsome Therapeutics Announces Closing of $9.5 Million Registered Direct Offering” on December 06, 2017. More interesting news about Axsome Therapeutics, Inc. (NASDAQ:AXSM) were released by: and their article: “Axsome Therapeutics: An Undervalued Promising CNS Disease Company” published on June 07, 2016 as well as‘s news article titled: “Axsome Therapeutics to Present at Upcoming Investor Conferences” with publication date: July 25, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.